Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Small-Cap · Franklin Templeton

Putnam Small Cap Value Fund Class A Shares (PSLAX)

Ticker PSLAX · · Holdings as of May 31, 2026

Expense ratio
1.1%$110/yr per $10k
5-yr return
+9.5%annualized
1-yr return
−0.8%as of Dec 2025
Net assets
$296.9Mall share classes
Holdings
128

Bottom line

Is PSLAX a good fund? The bottom line

PSLAX is the Class A share class of Putnam Small Cap Value Fund, a managed small-cap mutual fund from Franklin Templeton.

Annual fees run 1.1% — about $110 a year on every $10,000 invested, more expensive than 60% of small-cap funds we track.

It returned −0.8% over one year, +9.5% a year over five years, +8.3% a year over ten (as of Dec 31, 2025, per its prospectus).

With $297 million in net assets and 128 holdings, its largest position is Putnam Cash Collateral Pool LLC (17.5%) and the top 10 make up 30.2% of the portfolio.

This share class carries a front-end sales charge of up to 5.75%; a no-load class or ETF alternative can avoid it.

What stands out

  • 5-year return beat 77% of category peers

What to watch

  • Front-end sales load up to 5.75%
  • 12b-1 marketing fee of 0.25% a year

Updated Nov 19, 2026

What PSLAX invests in

The fund seeks capital appreciation.

The fund invests mainly in common stocks of small U.S. companies, with a focus on value stocks. Under normal circumstances, the fund invests at least 80% of its net assets, plus the amount of any borrowings for investment purposes, in equity securities of value companies of a size similar to those in the Russell 2000 Index over the past six months. This policy may be changed only after 60 days notice to shareholders. As of April 30, 2026, the index was composed of companies having market capitalizations of between approximately $18.3 million and $80.5 billion. The Investment Manager, as defined below, considers an issuer to be a value company if (i) the issuer is included in an index which is representative of value companies, (ii) the issuer is classified as a value company by an independent third party, and/or (iii) the Investment Manager believes the issuer is currently undervalued…

From the fund's prospectus (filed Jun 23, 2026).

PSLAX performance

Fund calendar-year total returns, 2016–2025 2016: +26.6%; 2017: +7.9%; 2018: −19.8%; 2019: +23.9%; 2020: +3.6%; 2021: +39.5%; 2022: −13.4%; 2023: +23.5%; 2024: +6.2%; 2025: +5.2% +27% 2016 +8% 2017 −20% 2018 +24% 2019 +4% 2020 +40% 2021 −13% 2022 +24% 2023 +6% 2024 +5% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
PSLAX−0.8%+9.5%+8.3%
Small-Cap median+7.6%+7.0%+9.2%

Source: Fund prospectus, as of Dec 31, 2025

Full PSLAX performance history →

What PSLAX costs

On a $10,000 investment, PSLAX's 1.1% expense ratio costs about $110 a year. The prospectus estimates $1,839 in total costs over 10 years (assuming 5% annual returns). The median small-cap fund charges 0.99%.

See the full PSLAX fee table →

PSLAX top 10 holdings

#Holding% of fund
1Putnam Cash Collateral Pool LLC17.51%
2Vishay Intertechnology, Inc.1.74%
3Veracyte, Inc.1.61%
4Cohu, Inc.1.58%
5BrightSpring Health Services, Inc.1.45%
6LifeStance Health Group, Inc.1.41%
7IBEX Holdings Ltd.1.29%
8Bel Fuse, Inc.1.25%
9Five Star Bancorp1.19%
10Nicolet Bankshares, Inc.1.19%

Source: SEC Form N-PORT, period ended May 31, 2026

The top 10 make up 30.2% of the fund. See all top 25 holdings and asset mix →

Alternatives to PSLAX

More funds like PSLAX →

PSLAX FAQ

What is the expense ratio of PSLAX?
PSLAX's expense ratio is 1.1%, which works out to about $110 a year for every $10,000 invested. The prospectus estimates total costs of $1,839 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is PSLAX a good investment?
It depends on your goals, but the data points to: 5-year return beat 77% of category peers; front-end sales load up to 5.75%; 12b-1 marketing fee of 0.25% a year. This is general information, not personalized advice.
What does PSLAX hold?
PSLAX's largest holdings are Putnam Cash Collateral Pool LLC (17.5%), Vishay Intertechnology, Inc. (1.7%), Veracyte, Inc. (1.6%), Cohu, Inc. (1.6%), BrightSpring Health Services, Inc. (1.5%). It holds 128 positions in total as of May 31, 2026 (SEC Form N-PORT).
What is PSLAX's 5-year return?
PSLAX returned +9.5% a year over the five years ending Dec 31, 2025, and +8.3% a year over ten years. Past performance does not guarantee future results.
Does PSLAX have a sales load?
Yes. PSLAX has a maximum front-end sales charge of 5.75%. It may charge a deferred sales charge of up to 1% if sold early.
Who manages PSLAX?
PSLAX is offered by Franklin Templeton through Putnam Investment Funds.